Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 17, 2021

BioXcel reports promising results for prostate cancer drug

PHOTO | STEVE LASCHEVER BioXcel Therapeutics CEO Vimal Mehta
By Liese Klein

New Haven-based BioXcel Therapeutics, Inc. reported promising results this week for BXCL701, its drug for prostate cancer. 

In ongoing Phase 1b/2 clinical trials, all of the patients in the study showed a decline in tumor size and other signs of effective treatment. The patients had been diagnosed with adenocarcinoma, an aggressive prostate cancer for which there are few available treatment options.

BioXcel’s drug was administered along with pembrolizumab, an immunotherapy drug. 

BioXcel Senior Vice President and Chief Medical Officer Dr. Vincent J. O’Neill said, “These data lay a strong foundation for the broad potential of BXCL701 in combination with pembrolizumab. We believe BXCL701 has the potential to be the most advanced orally available innate immune activator and to inflame the tumor micro-environment, thus making tumors more responsive to immunotherapies.”

According to the company, BXCL701 may make tumors more detectable by a patient’s immune system, allowing it to mobilize a strong anti-cancer response. A study of the drug's effectiveness against small-cell neuroendocrine carcinoma continues to enroll patients.

In addition to its prostate cancer drug, BioXcel is developing BXCL501, a treatment for the agitation associated with psychiatric and neurological disorders. The publicly traded company uses artificial intelligence to develop therapeutics in the neuroscience and immuno-oncology fields.

In anticipation of FDA approval of its psychiatric drug, BioXcel sold 3.15 million shares of common stock in July, raising $100 million in a public offering. 

Contact Liese Klein at lklein@newhavenbiz.com.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF